Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|---|---|
Income Statement | ||||
Total Revenue | 71.08M | 65.44M | 45.23M | 25.92M |
Gross Profit | 62.01M | 56.75M | 38.16M | 21.49M |
EBITDA | -43.74M | -37.71M | -26.51M | -35.06M |
Net Income | -44.50M | -40.45M | -29.46M | -37.16M |
Balance Sheet | ||||
Total Assets | 213.47M | 225.41M | 58.92M | 86.46M |
Cash, Cash Equivalents and Short-Term Investments | 182.70M | 194.37M | 34.49M | 68.23M |
Total Debt | 21.76M | 21.96M | 14.20M | 18.22M |
Total Liabilities | 20.76M | 34.25M | 171.17M | 172.86M |
Stockholders Equity | 180.88M | 191.16M | -112.25M | -86.40M |
Cash Flow | ||||
Free Cash Flow | -39.90M | -36.38M | -30.14M | -32.52M |
Operating Cash Flow | -38.18M | -35.04M | -29.16M | -32.00M |
Investing Cash Flow | -30.56M | -1.60M | -1.76M | -1.40M |
Financing Cash Flow | 192.68M | 196.52M | -2.82M | 49.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $719.68M | 36.60 | 23.81% | 1.14% | 11.04% | 9.84% | |
63 Neutral | $601.64M | ― | -7.22% | ― | 18.81% | 67.41% | |
52 Neutral | $549.38M | 45.80 | -36.78% | ― | 1.34% | -530.36% | |
50 Neutral | $514.36M | ― | -29.16% | ― | 25.77% | 49.44% | |
48 Neutral | $555.88M | ― | 26.25% | ― | ― | ― | |
46 Neutral | C$201.68M | -3.23 | -23.14% | 1.87% | 20.75% | -0.36% | |
45 Neutral | $322.66M | ― | -11.98% | ― | 46.69% | 46.68% |
On July 7, 2025, Ceribell, Inc. announced it filed complaints against Natus Medical Incorporated with the U.S. International Trade Commission and the U.S. District Court for the District of Delaware, alleging patent infringement and unfair competition related to its EEG headband and electrode design. Ceribell seeks to protect its intellectual property and maintain fair competition, requesting an investigation and exclusion order to prevent the importation of infringing Natus products into the U.S., highlighting its commitment to innovation in point-of-care EEG technology.
The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.
Ceribell, Inc. and Stanford University have amended their exclusive agreement, initially effective from June 15, 2015, to extend the exclusivity of Ceribell’s license for certain portable brain wave activity devices. On June 12, 2025, Ceribell exercised an option to extend this exclusivity by paying a $250,000 fee, which impacts the company’s operations by securing continued access to patented technology.
The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.
On June 10, 2025, Ceribell, Inc. held its Annual Meeting of Stockholders, where two key proposals were voted on. The stockholders elected Juliet Tammenoms Bakker and Lucian Iancovici, M.D. as Class I directors to serve until the 2028 meeting, and approved the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.